Premium
Commercial recreational pharmacology as the next drug problem
Author(s) -
Knopf Alison
Publication year - 2020
Publication title -
the brown university child and adolescent psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7567
pISSN - 1527-8395
DOI - 10.1002/cpu.30534
Subject(s) - pleasure , cannabis , recreational drug , recreation , addiction , nicotine , drug , nicotine addiction , clinical pharmacology , psychology , psychiatry , medicine , pharmacology , gerontology , political science , law , psychotherapist
Robert L. DuPont, M.D., president of the Institute for Behavior and Health Inc. in Rockville, Maryland, and Sharon Levy, M.D., M.P.H., director of the Adolescent Substance Use and Addiction Program at Boston Children's Hospital in Boston, Massachusetts, and associate professor in pediatrics with Harvard Medical School, shared an important message with us last month. It's about what they call “commercial recreational pharmacology,” which they define as “the personally controlled use of psychoactive drugs that super‐stimulate brain reward for pleasure.” There are few of these in the United States now, but young people use them: nicotine, cannabis (legal in some places), and, of course, alcohol.